BiotechTube

Human regular insulin + Insulin lispro + Insulin glargine

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperglycemia

Conditions

Hyperglycemia

Trial Timeline

Mar 1, 2011 → Nov 1, 2011

NCT ID
NCT01136746

About Human regular insulin + Insulin lispro + Insulin glargine

Human regular insulin + Insulin lispro + Insulin glargine is a phase 3 stage product being developed by Eli Lilly for Hyperglycemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01136746. Target conditions include Hyperglycemia.

What happened to similar drugs?

3 of 4 similar drugs in Hyperglycemia were approved

Approved (3) Terminated (1) Active (0)
✅Dapagliflozin + Sliding scale insulinAstraZenecaApproved
✅NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
✅insulin glargine + insulin glargine + insulin glargineSanofiApproved
❌insulin glargine recombinant + therapeutic insulinSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01136746Phase 3Terminated

Competing Products

9 competing products in Hyperglycemia

See all competitors
ProductCompanyStageHype Score
Exenatide + InsulinEli LillyPhase 2/3
38
Dapagliflozin + Sliding scale insulinAstraZenecaApproved
43
GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200MerckPhase 1
29
liraglutide + placeboNovo NordiskPre-clinical
26
Olanzapine + ZiprasidonePfizerPre-clinical
26
NPH insulin plus Complete Insulin Orders + Complete Insulin OrdersSanofiApproved
43
insulin glargine + insulin glargine + insulin glargineSanofiApproved
43
Lantus® (insulin glargine)SanofiPhase 1
29
insulin glargine recombinant + therapeutic insulinSanofiPhase 3
32